

Gender-Related Differences in Risk Profile in Young Patients with St-Elevation Myocardial Infarction a 7-Year Single Centre Experience

Chiara Lazzeri, MD^{*}, Marco Chiostrì, MD, Maria Grazia D'Alfonso, MD¹, Alessio Mattesini, MD¹, Gian Franco Gensini, MD¹, and Serafina Valente, MD¹

¹Intensive Cardiac Coronary Unit, Heart and Vessel Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

Abstract

Few studies have focused on acute ST-elevation myocardial infarction (STEMI) in young patients. We aimed to analyze the incidence, risk factors, management, and prognosis of STEMI in 182 consecutive young patients (age ≤ 50 years) (2004 to 2012), focusing on gender-related differences.

Males (87.4%) showed higher BMI values ($p=0.004$), a higher incidence of overweight and obesity ($p=0.016$). Diabetes was more frequent in females ($p=0.02$).

The main findings of your investigation are as follows: a) over the 7 year-study period the percentage of young STEMI patients did not change; b) the risk profile of males was different from that of females who showed a higher incidence of diabetes, while the frequency of smoking and hypertension was comparable between the two subgroups; c) no gender-related difference was detectable in management also in regard to medical therapy at discharge; d) young STEMI patients showed a good prognosis at short and long term.

Keywords

Young STEMI; Gender; BMI; Diabetes; Obesity

***Corresponding author:** Chiara Lazzeri, MD, Intensive Cardiac Care Unit Heart and Vessel Department, Viale Morgagni 85, 50134 Florence, Italy, Tel: +39-55-7947518; Fax: +39-55-7947518; E-mail: lazzeric@libero.it

Received Date: 09th July 2014

Accepted Date: 12th August 2014

Published Date: 16th August 2014

Citation: Lazzeri C, Chiostrì M, Grazia D'Alfonso M, Mattesini A, Franco Gensini G, et al. (2014) Gender-Related Differences in Risk Profile in Young Patients with St-Elevation Myocardial Infarction a 7-Year Single Centre Experience. Enliven: Clin Cardiol Res 1(1): 002.

Copyright: © 2014 Dr. Chiara Lazzeri. This is an Open Access article published and distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Introduction

On currently available evidence, young patients represent 0.4%–19% of all acute coronary syndrome (ACS) cases, depending on the cut-off age used [1–12].

Few studies have focused on acute ST-elevation myocardial infarction (STEMI) in young patients but, despite the fact that young patients are a relatively small proportion of those having STEMI, it is important to recognize these patients for the purpose of risk factor modification and secondary prevention in younger patients.

The present investigation was aimed to analyze the incidence, risk factors, management, and prognosis of STEMI in young patients (age ≤ 50 years) consecutively admitted to our Intensive Cardiac Unit from 2004 to 2012, focusing on gender-related differences.

Methods

From 1st January 2004 to 31st December 2012, 1724 consecutive patients with STEMI (within 12 hours from symptoms' onset) were admitted to our ICCU [13], after primary percutaneous coronary intervention (PCI) [13,14]. In our hospital, in Florence, the reperfusion strategy of STEMI patients is represented by primary PCI [15–18]. STEMI patients are first evaluated by the medical emergency system staff in the prehospital setting and then directly admitted to the catheterization laboratory or transferred to it after rapid stabilization in the emergency department. After primary PCI, patients are admitted to our ICCU.

Among the 1724 STEMI patients, 182 (11.8%) were aged ≤ 50 years and constituted the population of the present investigation.

The presence of comorbidities was determined by taking the patients' history directly.

On ICCU admission, after PCI, in a fasting blood sample the following parameters were measured: glucose (mg/dl), insulin (mUI/l), glycated hemoglobin (%), troponin I (Tn I, ng/ml), uric acid (mg/dl), NT-pro Brain Natriuretic Peptide (NT-BNP) (pg/ml) (20), total cholesterol (mg/dl), triglycerides (mg/dl), fibrinogen (mg/dl), leukocytes count ($10^3/\mu\text{l}$), erythrocyte sedimentation rate (ESR) and C-Reactive Protein (CRP, mg/dl), fibrinogen (mg/dl), total cholesterol (mg/dl) HDL (mg/dl), triglycerides (mg/dl). Admission creatinine (mg/dl) was measured in order to calculate admission glomerular filtration rate ($\text{ml}/\text{min}/1.73 \text{ m}^2$) [19]. Glucose, creatinine and Tn I were measured three times a day during ICCU stay and peak values for each variable were considered. Acute insulin resistance was defined according to the Homeostatic Model Assessment index, as previously described. Subjects whose values exceeded the sex-specific 75th percentile (i.e. 1.80 for women and 2.12 for men) were considered to have insulin resistance (HOMA-IR) [15,16].

Transthoracic 2-dimensional echo-cardiography was performed in order to measure left ventricular ejection fraction (LVEF) on admission and at discharge.

Worsening creatinine was calculated as the difference between the patient's admission creatinine and peak creatinine during hospitalization. Worsening in renal function (WRF) was defined as an increased in creatinine $\geq 0.3 \text{ mg}/\text{dl}$, as previously described [20,21].

Ventilatory support, renal replacement therapy (continuous venous-venous ultrafiltration - CVVHDF) and intra-aortic balloon pump were used, when need [14,22].

The primary endpoint was all-cause death at follow-up.

The study protocol was in accordance with the Declaration of Helsinki and approved by the local Ethics Committee. Informed consent was obtained in all patients before enrollment.

Statistical Analysis

Statistical analysis has been conducted with IBM-SPSS Statistics 20.0 for Windows software (SPSS Inc, Chicago, IL). In all cases, a two-tailed p-value <0.05 has been considered statistically significant. Continuous variables have been reported as median (interquartile range: "IR"); categorical variables are depicted as frequency (percentage). Comparisons were made with Mann-Whitney U test and chi-square or Fisher's exact test, as needed. Trends through years 2004-2012 have been investigated by means of linear regression analysis. Several logistic regression models were constructed to investigate whether age (1 year step), gender (male vs. female), body mass index (BMI, 1 Kg/m^2 step), known diabetes mellitus, left ventricle ejection fraction (LVEF) at admission (1% step), serum glucose at admission (1 g/dL step) and estimated glomerular filtration rate (eGFR, calculated by MDRD formula, 1 $\text{ml}/\text{min}/1.73\text{m}^2$ step) at admission were related to total death (both in-ICCU death and at long term follow-up); only unadjusted odds ratios have been reported due to the small number (seven) of events recorded.

Results

Table 1 shows the differences in risk factors between elderly and young patients. Among elderly patients, a higher percentage of females was detectable ($p<0.001$) as well as a higher incidence of diabetes mellitus ($p=0.004$) COPD ($p=0.002$), previous PCI ($p=0.041$), previous MI ($p=0.019$) and hypertension ($p<0.001$). The incidence of overweight (BMI >25 to ≤ 30) and obese (BMI > 30) was comparable between the two subgroups.

| | All patients n=1542 | Young <= 50 years n=182 (11.8%) | Elderly > 50 years n=1360 (88.2%) | p value |
|---|-------------------------|---------------------------------------|---|---------|
| Age (yrs), median (IR) | 67 (58-77) | 47 (44-49) | 70 (61-78) | <0.001 |
| M/F | 1127/415 (73.1/26.9) | 159/23 (87.4/12.6) | 968/392 (71.2/28.8) | <0.001 |
| BMI (Kg/m^2), median (IR) | 26.1 (23.9-27.9) | 26.3 (24.7-28.6) | 26.0 (23.8-27.8) | 0.023 |
| BMI (Kg/m^2), frequency (%) | | | | 0.151 |
| ≤ 25 | 556 (36.2) | 56 (30.8) | 503 (37.0) | |
| >25 to ≤ 30 | 771 (50.3) | 95 (52.2) | 680 (50.0) | |
| >30 | 207 (13.5) | 31 (17.0) | 177 (13.0) | |
| History of, frequency (%) | | | | |
| Diabetes mellitus | 362 (23.5) | 27 (14.8) | 339 (24.9) | 0.004 |
| Smoking | 940 (61.0) | 152 (83.5) | 788 (57.9) | <0.001 |
| COPD | 137 (8.9) | 5 (2.7) | 132 (9.7) | 0.002 |
| Previous PCI | 211 (13.7) | 16 (8.8) | 195 (14.3) | 0.041 |
| Previous MI | 214 (13.9) | 15 (8.2) | 199 (14.6) | 0.019 |
| Hypertension | 820 (53.2) | 60 (33.0) | 760 (55.9) | <0.001 |

BMI: body mass index; COPD: chronic obstructive pulmonary disease; PCI: percutaneous coronary intervention; MI: myocardial infarction

Table 1 . Differences in risk factors between elderly and young patients

Our population comprises 182 patients. The percentage of young STEMI patients (aged ≤ 50 years) observed each year is depicted in Figure 1: no difference was detectable in the incidence of young STEMI through the study period (Chi-square 4.9, $p=0.773$).

As shown in Table 2, in our series, 159 patients (87.4%) were males who showed higher BMI values ($p=0.004$), a higher incidence of overweight and obesity ($p=0.016$). Diabetes was more frequent in females ($p=0.02$).

Anterior myocardial infarction was more frequent in females ($p=0.011$). No difference was observed in mortality rates during ICCU stay and at follow-up between the two subgroups. Throughout the study period, the percentage of diabetic patients did not change [Figure 2] while the percentage of hypertensive patients progressively declined ($R^2=0.48$, $p=0.039$). As depicted in Figure 4, the percentage of overweight patients declined ($R^2=0.45$, $p=0.047$) while the incidence of obesity did not change ($p=0.530$) [Figure 4a and 4b respectively].

| | All patients n=182 | Males n=159 (87.4%) | Females n=23 (12.6%) | p value |
|--|--------------------|---------------------|----------------------|---------|
| Age (yrs), median (IR) | 47 (44-49) | 47 (44-49) | 46 (44-48) | 0.434 |
| BMI (Kg/m ²), median (IR) | 26.3 (24.7-28.6) | 26.3 (24.9-28.7) | 23.9 (22.7-26.7) | 0.004 |
| BMI (Kg/m ²), frequency (%) | | | | 0.016 |
| ≤ 25 | 56 (30.8) | 43 (27.0) | 13 (56.5) | |
| >25 to ≤ 30 | 95 (52.2) | 87 (54.7) | 8 (34.8) | |
| >30 | 31 (17.0) | 29 (18.2) | 2 (8.7) | |
| History of, frequency (%) | | | | |
| Diabetes mellitus | 27 (14.8) | 20 (12.6) | 7 (30.4) | 0.024 |
| Smoking | 152 (83.5) | 135 (84.9) | 17 (73.9) | 0.184 |
| COPD | 5 (2.7) | 3 (1.9) | 2 (8.7) | 0.121* |
| Previous PCI | 16 (8.8) | 15 (9.4) | 1 (4.3) | 0.421 |
| Previous MI | 15 (8.2) | 12 (7.5) | 3 (13.0) | 0.370 |
| Hypertension | 60 (33.0) | 52 (32.7) | 8 (34.8) | 0.843 |
| Symptom door-to-balloon time (minutes), median (IR) | 195 (120 to 300) | 195 (120 to 290) | 195 (140 to 375) | 0.263 |
| Admission Systolic arterial pressure (mmHg), median (IR) | 125 (110-140) | 125 (110-140) | 120 (110-130) | 0.174 |
| Admission heart rate (bpm), median (IR) | 76 (67-89) | 75 (66-89) | 78 (71-88) | 0.232 |
| AMI location, frequency (%) | | | | 0.011 |
| Anterior | 98 (53.8) | 79 (49.7) | 19 (82.6) | |
| Inferior | 72 (39.6) | 68 (42.8) | 4 (17.4) | |
| Other | 12 (6.6) | 12 (7.5) | 0 (0.0) | |
| Coronary artery disease, frequency (%) | | | | 0.203 |
| 1-vessel | 108 (59.3) | 92 (57.9) | 16 (69.6) | |
| 2-vessel | 42 (23.1) | 36 (22.6) | 6 (26.1) | |
| 3-vessel | 32 (17.6) | 31 (19.5) | 1 (4.3) | |
| PCI failure, frequency (%) | 3 (1.7) | 2 (1.3) | 1 (4.5) | 0.325* |
| Killip, frequency (%) | | | | 0.186 |
| 1-II | 170 (93.4) | 150 (94.3) | 20 (87.8) | |
| III-IV | 12 (6.6) | 9 (5.7) | 3 (13.0) | |
| Admission LVEF (%), median (IR) | 45 (40-52) | 45 (40-52) | 45 (40-51) | 0.695 |
| Discharge LVEF (%), median (IR) | 48 (43-54) | 50 (44-55) | 46 (42.5-50) | 0.164 |
| In-ICCU mortality, frequency (%) | 4 (2.2) | 3 (1.9) | 1 (4.3) | 0.420* |
| Total mortality, frequency (%) | 7/125 (5.6) | 5/111 (4.5) | 2/14 (14.3) | 0.134 |
| total follow-up (months), median (IR) | 37 (15-63) | 34 (14-62) | 52 (32-65) | 0.315 |

*Fisher's exact test

BMI: body mass index; COPD: chronic obstructive pulmonary disease; PCI: percutaneous coronary intervention; MI: myocardial infarction; AMI: acute myocardial infarction; LVEF: left ventricular ejection fraction, ICCU: intensive cardiac care unit;

Table 2 Clinical and angiographic data of the study population







Table 3 depicts bio-chemical data. In the comparison between males and females, no difference was detectable except for higher values of uric acid observed in males ($p < 0.001$). The use of devices and well as the incidence of complications were comparable between males and females [Table 4]. During ICCU stay, males were more frequently administered ACE-inhibitors/

angiotensin receptor blockers ($p = 0.029$), while no differences were observed in medications at discharge [Table 5].

At univariable regression analysis, admission glycemia and LVEF was associated with total mortality ($p < 0.001$ and $p < 0.001$, respectively) [Table 6].

| | All patients n=182 | Males n=159 (87.4%) | Females n=23 (12.6%) | p value |
|---|---------------------------|--------------------------|-------------------------|---------|
| Admission Glucose (g/L) | 1.12 (1.01-1.31) | 1.11 (1.00-1.31) | 1.20 (1.02-1.44) | 0.460 |
| Peak glucose (g/L) | 1.27 (1.12-1.45) | 1.26 (1.11-1.44) | 1.33 (1.18-1.46) | 0.406 |
| Admission glycemia > 140 mg/dL, frequency (%) | 36 (19.8) | 30 (18.9) | 6 (26.1) | 0.417 |
| Discharge glucose (g/L) | 0.95 (0.86-1.13) | 0.94 (0.86-1.11) | 1.04 (0.84-1.31) | 0.427 |
| HbA1c > 6.5%, frequency (%) | 21 (11.5) | 18 (11.3) | 3 (13.0) | 0.809 |
| Insulinemia (UI/L) | 9.1 (5.2-17) | 9.3 (5.0-16.8) | 8.9 (6.2-15.8) | 0.815 |
| HOMA index high, frequency (%) | 10/ ₁₀₅ (9.5) | 8/ ₉₂ (8.7) | 2/ ₁₃ (15.4) | 0.442 |
| Peak Tn I (ng/mL) | 86.0 (41.8-179.0) | 80.6 (41.9-180.1) | 105.0 (41.9-105.0) | 0.886 |
| NT-proBNP (pg/mL) | 544 (215-1087) | 451 (214-1056) | 587 (325-1559) | 0.330 |
| Uric acid (mg/dL) | 5.5 (4.6-6.3) | 5.6 (4.8-6.7) | 4.2 (3.6-5.2) | <0.001 |
| ESR (mm/h) | 14 (6+26) | 14 (6-25) | 18 (6-38) | 0.529 |
| Leucocytes (*10 ³ /μL) | 12.1 (9.4-15.2) | 119 (9.4-15.1) | 13.3 (10.4-15.6) | 0.320 |
| hs-CRP positivity, frequency (%) | 46/ ₁₁₃ (40.7) | 41/ ₉₉ (41.4) | 5/ ₁₄ (35.7) | 0.685 |
| Fibrinogen (mg/dL) | 360 (299-410) | 362 (302-413) | 334 (292-394) | 0.327 |
| Admission eGFR (ml/min/1.73m ²) | 98.4 (84.9-116.0) | 98.5 (85.3-116.2) | 95.9 (83.6-111.0) | 0.880 |
| Nadir eGFR (ml/min/1.73m ²) | 87.2 (75.7-103.5) | 87.2 (75.7-96.8) | 88.8 (82.2-97.8) | 0.958 |
| Total cholesterol (mg/dL) | 197 (165-225) | 194 (163-225) | 181 (161-220) | 0.341 |
| HDL cholesterol (mg/dL) | 40 (34-47) | 39 (34-46) | 41 (35-51) | 0.180 |
| Triglycerides (mg/dL) | 123 (91-172) | 123 (94-163) | 103 (62-190) | 0.154 |

All values are medians (IR) unless otherwise specified.

HOMA: homeostatic model assessment; NT-pro BNP: N terminal pro brain natriuretic peptide; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; eGFR: estimated glomerular filtration rate.

Table 3 Laboratory data

| | All patients n=182 | Males n=159 (87.4%) | Females n=23 (12.6%) | p value |
|--------------------------|--------------------|---------------------|----------------------|---------|
| Mechanical ventilation | 11 (6.0) | 10 (6.3) | 1 (4.3) | 0.715 |
| Non invasive ventilation | 2 (1.1) | 1 (0.6) | 1 (4.3) | 0.237* |
| CVVHDF | 2 (1.1) | 2 (1.3) | 0 (0.0) | 1* |
| IABP | 31 (17.0) | 27 (17.0) | 4 (17.4) | 0.961 |
| Complications | 26 (14.3) | 21 (13.2) | 5 (21.7) | 0.274 |
| WRF | 8 (4.4) | 6 (3.8) | 2 (8.7) | 0.282 |
| transfusions | 5 (2.7) | 4 (2.5) | 1 (4.3) | 0.495* |

All values are frequencies (%)

*Fisher's exact test

CVVHDF: continuous venous-venous ultrafiltration; IABP: intra-aortic balloon pump; WRF: worsening renal failure.

Table 4 Devices and complications

| | All patients n=182 | Males n=159 (87.4%) | Females n=23 (12.6%) | p value |
|--------------------------|--------------------|---------------------|----------------------|---------|
| During ICCU | | | | |
| β-blockers | 169 (92.9) | 147 (92.5) | 22 (95.7) | 0.578 |
| ACEi - ARB | 165 (90.7) | 147 (92.5) | 18 (78.3) | 0.029 |
| Calcium channel blockers | 4 (2.2) | 3 (1.9) | 1 (4.3) | 0.420* |
| Diuretics | 106 (58.2) | 91 (57.2) | 15 (65.2) | 0.468 |
| ASA | 182 (100) | 159 (100) | 23 (100) | 1* |
| Clopidogrel | 175 (96.2) | 154 (96.9) | 21 (91.3) | 0.196 |
| IIBIIa GP inhibitors | 159 (87.4) | 140 (88.1) | 19 (82.6) | 0.463 |
| Statin | 177 (97.3) | 156 (98.1) | 21 (91.3) | 0.121* |
| At discharge | | | | |
| β-blockers | 162 (91.0) | 140 (89.7) | 22 (100) | 0.115 |
| ACEi - ARB | 158 (88.8) | 141 (90.4) | 17 (77.3) | 0.068 |
| Ca channel blockers | 3 (1.7) | 2 (1.3) | 1 (4.5) | 0.328* |
| Diuretics | 68 (38.2) | 59 (37.8) | 9 (40.9) | 0.780 |
| ASA | 177 (99.4) | 155 (99.4) | 22 (100) | 1* |
| Clopidogrel | 154 (86.5) | 136 (87.2) | 18 (81.8) | 0.491 |
| Statins | 173 (97.2) | 152 (97.4) | 21 (95.5) | 0.487* |

All values are frequencies (%)

*Fisher's exact test

ARB: angiotensin receptor blockers, IIBIIa GP inhibitors: IIBIIa glycoprotein inhibitors

Table 5 Medications

| | Unadj.HR | 95% CI | p value |
|--|----------|------------|---------|
| Age (1 year step) | 1.06 | 0.89-1.25 | 0.517 |
| Admission LVEF (1% step) | 0.88 | 0.82-0.95 | <0.001 |
| Gender (M vs. F) | 0.30 | 0.06-1.52 | 0.145 |
| Admission glycemia (1 g/dL step) | 4.46 | 2.16-9.20 | <0.001 |
| Admission eGFR (1mL/min/1.73m ² step) | 0.99 | 0.96-1.02 | 0.405 |
| Diabetes | 2.16 | 0.42-11.15 | 0.357 |
| BMI (1 Kg/m ² step) | 1.07 | 0.88-1.31 | 0.507 |

LVEF: left ventricular ejection fraction, eGFR: estimated glomerular filtration rate; BMI: body mass index.

Table 6 Univariable regression analysis

Discussion

The main findings of your investigation, performed in 182 consecutive STEMI patients aged ≤ 50 years submitted to primary PCI, are as follows: a) over the 7 year-study period the percentage of young STEMI patients did not change; b) the risk profile of males was different from that of females who showed a higher incidence of diabetes, while the frequency of smoking and hypertension was comparable between the two subgroups; c) no gender-related difference was detectable in management also in regard to medical therapy at discharge; d) young STEMI patients showed a good prognosis at short and long term.

In our series the incidence of young STEMI, which was comparable to that reported in previous studies [23,24], did not change over the 7 year study period, thus underlying the need of more efficacious policies for primary prevention in young subjects.

While smoking and hypertension were confirmed as a common risk factors [5,24-26], both in males and females, gender-related differences in risk profile were, for the first time, detectable in our series. Females showed a higher incidence of diabetes which remained unchanged over the study period. Our population comprised all Caucasian subjects with no significant differences in dietary habits since almost all subjects followed Mediterranean diet (3 patients were while the incidence of vegetarians), Our finding may be explained with the higher prevalence of overweight and obesity in males within our population, as recently reported [27], though, in our investigation, it showed a progressive reduction over time. Our findings suggest the need of different strategies for primary (and secondary) prevention according to gender.

In our population, while the incidence of hypertension and overweight decline throughout the study period, obesity and diabetes remained

unchanged, thus suggesting that in recent years the occurrence of STEMI in young patients was more frequently associated with diabetes and obesity. In a small subset of 36 young (< 45 years old) STEMI patients, Basoor et al. [28] reported a high incidence of obesity (78%), confirming previous data by Chau et al. [24] who documented that obesity was detectable in the 48% of patients (27/99 patients) and by Ueda et al. [10] reporting an incidence of obesity of 42% (28/66 patients). However, many investigations performed in young AMI patients mostly in the '80s and '90s, BMI and/or obesity were not considered as risk factors [1-4,29].

In our study, addressing for the first time gender-related differences in management in young STEMI, we observed that males and females were equally treated in terms of devices and medications (during ICCU stay and at discharge).

In agreement with previous reports [1-2,24,29], young STEMI patients exhibited a good prognosis at short and long terms. In our series, factors associated, at univariable regression analysis, with long term prognosis was represented by the extent of myocardial injury (as inferred by LVEF) and admission glycemia. These findings strongly suggest the need of a more intensive monitoring program in the subset of young STEMI patients presenting with larger infarct size and subsequent more severe metabolic derangement.

Overall, on a clinical ground, our data strongly suggest the need of efficacious primary and secondary prevention policies gender-tailored.

Conflict of Interest

No

References

1. Chen YL, Bhasin A, Youssef AA, Wu CJ, Yang CH, et al. (2009) Prognostic factors and outcomes in young chinese patients with acute myocardial infarction undergoing primary coronary angioplasty. *Int Heart J* 50: 1-11.
2. Chan MY, Woo KS, Wong HB, Chia BL, Sutandar A, et al. (2006) Antecedent risk factors and their control in young patients with a first myocardial infarction. *Singapore Med J* 47: 27-30.
3. Morillas P, Bertomeu V, Pabon P, Ancillo P, Bermejo J, et al. (2007) Characteristics and outcome of acute myocardial infarction in young patients. The PRIAMHO II study. *Cardiology* 107: 217-225.
4. Hoit BD, Gilpin EA, Henning H, Maisel AA, Dittrich H, et al. (1986) Myocardial infarction in young patients: an analysis by age subsets. *Circulation* 74: 712-721.
5. Doughty M, Mehta R, Bruckman D, Das S, Karavite D, et al. (2002) Acute myocardial infarction in the young –The University of Michigan experience. *Am Heart J* 143: 56-62.
6. Rumboldt Z, Rumboldt M, Pesenti S, Polic S, Miric D (1995) Peculiarities of myocardial infarction at young age in Southern Croatia. *Cardiologia* 40: 407-411.
7. Teixeira M, Sa I, Mendes JS, Martins L (2010) Acute coronary syndrome in young adults *Rev Port Cardiol* 29: 947-955.
8. Kanitz MG, Giovannucci SJ, Jones JS, Mott M (1996) Myocardial infarction in young adults: risk factors and clinical features. *J Emerg Med* 14: 139-145.
9. Siwach SB, Singh H, Sharma D, Katyal VK (1998) Profile of young acute myocardial infarction in Hararyana. *J Assoc Physicians India* 46: 424-426.
10. Ueda Y, Okada K, Ogasawara N, Oyabu J, Hirayama A, et al. (2007) Acute myocardial infarction without disrupted yellow plaque in young patients below 50 years old. *J Interv Cardiol* 20: 177-181.
11. Wolfe MW, Vacek JL (1988) Myocardial infarction in the young. Angiographic features and risk factor analysis of patients with myocardial infarction at or before the age of 35 years. *Chest* 94: 926-930.
12. Gotsman I, Lotan C, Mosseri M (2003) Clinical manifestations and outcome of acute myocardial infarction in very young patients. *Isr Med Assoc J* 5: 633-636.
13. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, et al. (2010) Guidelines on myocardial revascularization. *Eur Heart J* 31: 2501-2555.

14. Lazzeri C, Valente S, Chiostri M, Attanà P, Picariello C, et al. (2012) Impact of hypertension on short- and long-term prognoses in patients with ST elevation myocardial infarction and without previously known diabetes. *Heart Vessels* 27: 370-376.
15. Lazzeri C, Sori A, Chiostri M, Gensini GF, Valente S (2009) Prognostic role of insulin resistance as assessed by homeostatic model assessment index in the acute phase of myocardial infarction in nondiabetic patients submitted to percutaneous coronary intervention. *Eur J Anaesthesiol* 26: 856-862.
16. Lazzeri C, Valente S, Chiostri M, Attanà P, Mattesini A, et al. (2013) Hyperglycemia, acute insulin resistance, and renal dysfunction in the early phase of ST-elevation myocardial infarction without previously known diabetes: impact on long-term prognosis. *Heart Vessels*. [Epub ahead of print].
17. Valente S, Lazzeri C, Chiostri M, Giglioli C, Zucchini M, et al. (2012) Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry. *Eur J Prev Cardiol* 19: 233-240.
18. Buiatti E, Barchielli A, Marchionni N, Carrabba N, Valente S, et al. (2003) Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence). *Eur Heart J* 24: 1195-1203.
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150: 604-612.
20. Amin AP, Spertus JA, Reid KJ, Lan X, Buchanan DM, et al. (2010) The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality. *Am Heart J* 160: 1065-1071.
21. Lazzeri C, Valente S, Chiostri M, Picariello C, Attanà P, et al. (2012) ST-elevation myocardial infarction with preserved ejection fraction: the impact of worsening renal failure. *Int J Cardiol* 155: 170-172.
22. Valente S, Lazzeri C, Crudeli E, Chiostri M, Giglioli C, et al. (2012) Intraaortic balloon pump: incidence and predictors of complications in the Florence registry. *Clin Cardiol* 35: 200-204.
23. Moccetti T, Malacrida R, Pasotti E, Sessa F, Genoni M, et al. (1997) Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. *Arch Intern Med* 157: 865-869.
24. Chua SK, Hung HF, Shyu KG, Cheng JJ, Chiu CZ, et al. (2010) Acute ST-elevation myocardial infarction in young patients: 15 years of experience in a single center. *Clin Cardiol* 33: 140-148.
25. Barbash GI, White HD, Modan M, Diaz R, Hampton JR, et al. (1995) Acute myocardial infarction in the young: the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. *Eur Heart J* 16: 313-316.
26. Pineda J, Marin F, Roldan V, Valncia J, Marco P, et al. (2008) Premature myocardial infarction: clinical profile and angiographic findings. *Int J Cardiol* 126: 127-129.
27. O Connor JM, Millar SR, Buckley CM, Kearney PM, Perry IJ (2013) The prevalence and determinants of undiagnosed and diagnosed type 2 diabetes in middle-aged irish adults. *PLoS One* 8: e80504.
28. Basoor A, Cotant JF, Randhawa G, Janjua M, Badshah A, et al. (2011) High prevalence of obesity in young patients with ST elevation myocardial infarction. *Am Heart Hosp J* 9: E37-E40.
29. Zimmerman FH, Cameron A, Fisher LD, Nq G (1995) Myocardial infarction in young patients: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). *J Am Coll Cardiol* 26: 654-661.

Submit your manuscript at
<http://enlivenarchive.org/submit-manuscript.php>
New initiative of Enliven Archive

Apart from providing HTML, PDF versions; we also provide **video version** and deposit the videos in about 15 freely accessible social network sites that promote videos which in turn will aid in rapid circulation of articles published with us.